Entera Bio (NASDAQ:ENTX) Cut to “Strong Sell” at Wall Street Zen

by · The Markets Daily

Wall Street Zen downgraded shares of Entera Bio (NASDAQ:ENTX – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. UBS Group set a $9.00 target price on shares of Entera Bio in a research report on Friday, September 18th. Lifesci Capital assumed coverage on shares of Entera Bio in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, October 15th. Leerink Partners started coverage on shares of Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Entera Bio has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

Get Our Latest Analysis on ENTX

Entera Bio Trading Up 3.5%

Shares of ENTX stock opened at $3.25 on Friday. Entera Bio has a twelve month low of $0.91 and a twelve month high of $4.20. The stock has a fifty day simple moving average of $2.88 and a two-hundred day simple moving average of $1.96. The stock has a market capitalization of $565.24 million, a price-to-earnings ratio of -8.33 and a beta of 1.48.

Entera Bio (NASDAQ:ENTX – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Research analysts predict that Entera Bio will post -0.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

An institutional investor recently raised its position in Entera Bio stock. Renaissance Technologies LLC raised its position in shares of Entera Bio Ltd. (NASDAQ:ENTX – Free Report) by 338.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 473,442 shares of the company’s stock after buying an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 at the end of the most recent reporting period. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.

Further Reading